Lumakras plus Vectibix showed improved overall survival and response rates in KRAS G12C metastatic colorectal cancer, though ...

By 10 votes to two, the panel concluded that the CodeBreak-200 trial of KRASG12c-mutated non-small-cell lung cancer (NSCLC) was not strong enough to show conclusively that Lumakras (sotorasib ...

The FDA's conditional approval for Lumakras (sotorasib; formerly AMG-510) as a second-line treatment for KRAS G12c-mutated non-small cell lung cancer (NSCLC) has come more than two months ahead of ...

KRASG12C-targeted therapies like sotorasib and adagrasib have been approved, but resistance challenges persist, necessitating further research into RAS(ON) therapies. Revolution Medicines is ...

Patients in a Phase 3 clinical trial who received sotorasib and panitumumab lived longer, suggesting the combination therapy could become the new standard of care, according to a new City of Hope ...

Join Brian Lanman of Amgen as he outlines the strategies used to overcome these challenges, the screening approaches employed to identify starting points for these efforts, and the optimization ...

HAIKOU, August 24. /TASS/. An innovative American drug Lumakras (also known as Sotorasib) for lung cancer and other types of cancer may soon become available at Hainan Lecheng Medical Cluster ...

The company previously received US Food and Drug Administration (FDA) approval for its LUMAKRAS (sotorasib) and Vectibix (panitumumab) combination therapy for treating adults with KRAS G12C ...

In a study published in the Journal of Clinical Oncology, colorectal cancer patients who received a combination of two drugs, the small-molecule KRAS G12C inhibitor sotorasib combined with the ...